SLC5A2 and hydrops fetalis: The results of the SOLOIST-WHF and EMPULSE trials, showing clinical benefits after (semi-)acute hospitalization for HF, suggest that indications for SGLT2 inhibitors could extend to even more patients in the near future [40,43].